Join IAPMD and Dr. Emilė Radytė to explore new research into non-invasive brain stimulation for Premenstrual Dysphoric Disorder (PMDD) and review the recent study Validation of a Non-Invasive Brain Stimulation Device (Nettle™) to Manage Symptoms of PMDD .
After this session, viewers will:
Understand the neuroscience of PMDD, including the latest research on how cyclical hormone sensitivity impacts brain function and emotional regulation.
Understand the key barriers to accurate PMDD diagnosis, including the need for cycle tracking and symptom overlap with other conditions like ADHD and bipolar disorder.
Evaluate the potential role of the Nettle™ device as a non-invasive, non-hormonal, and non-medication treatment option for PMDD, especially for those who don't respond well to current therapies. This will include an exploration of results from a recent clinical trial assessing Nettle specifically for PMDD, where it is currently approved for pain and mood symptoms.
Identify the challenges and opportunities in integrating new PMDD treatments like Nettle™ into healthcare systems, including the importance of clinician awareness, patient advocacy, and coordinated care pathways.
Intended Audience:
Designed for anyone who wants to better understand PMDD with an interest in research, mental health, and emerging health technologies.
Hosted by: IAPMD and Emilė Radytė, PhD
Dr Emilė Radytė is a neuroscientist and science communicator whose work explores how hormonal changes shape brain function, mood, and behavior. A graduate of Harvard and Oxford, her research has focused on psychiatric applications and neurocognitive markers of response to brain stimulation treatments for depression.
She is the co-founder of Samphire Neuroscience, a company on a mission to provide brain-based solutions for women across the lifecycle. Its first product, Nettle™, is a CE-marked at-home neurotechnology device for the relief of menstrual-related pain and mood symptoms. Nettle™ is currently part of a PMDD study led by Queen Mary University of London, now in the reporting phase, and an NHS pilot study for endometriosis-related pain. Emilė is deeply passionate about advancing women’s health and closing the gender gap in neuroscience through evidence-based innovation.
Disclaimer: This event is for educational purposes and is not intended as medical advice. IAPMD does not endorse, sponsor, or encourage your use of the information or services presented and we accept no liability for the content. Please consult your trusted health professionals and your own values and beliefs when making decisions about your treatment and care.
Recorded: November 6, 2025
Join IAPMD and Dr. Emilė Radytė to explore new research into non-invasive brain stimulation for Premenstrual Dysphoric Disorder (PMDD) and review the recent study Validation of a Non-Invasive Brain Stimulation Device (Nettle™) to Manage Symptoms of PMDD .
After this session, viewers will:
Understand the neuroscience of PMDD, including the latest research on how cyclical hormone sensitivity impacts brain function and emotional regulation.
Understand the key barriers to accurate PMDD diagnosis, including the need for cycle tracking and symptom overlap with other conditions like ADHD and bipolar disorder.
Evaluate the potential role of the Nettle™ device as a non-invasive, non-hormonal, and non-medication treatment option for PMDD, especially for those who don't respond well to current therapies. This will include an exploration of results from a recent clinical trial assessing Nettle specifically for PMDD, where it is currently approved for pain and mood symptoms.
Identify the challenges and opportunities in integrating new PMDD treatments like Nettle™ into healthcare systems, including the importance of clinician awareness, patient advocacy, and coordinated care pathways.
Intended Audience:
Designed for anyone who wants to better understand PMDD with an interest in research, mental health, and emerging health technologies.
Hosted by: IAPMD and Emilė Radytė, PhD
Dr Emilė Radytė is a neuroscientist and science communicator whose work explores how hormonal changes shape brain function, mood, and behavior. A graduate of Harvard and Oxford, her research has focused on psychiatric applications and neurocognitive markers of response to brain stimulation treatments for depression.
She is the co-founder of Samphire Neuroscience, a company on a mission to provide brain-based solutions for women across the lifecycle. Its first product, Nettle™, is a CE-marked at-home neurotechnology device for the relief of menstrual-related pain and mood symptoms. Nettle™ is currently part of a PMDD study led by Queen Mary University of London, now in the reporting phase, and an NHS pilot study for endometriosis-related pain. Emilė is deeply passionate about advancing women’s health and closing the gender gap in neuroscience through evidence-based innovation.
Disclaimer: This event is for educational purposes and is not intended as medical advice. IAPMD does not endorse, sponsor, or encourage your use of the information or services presented and we accept no liability for the content. Please consult your trusted health professionals and your own values and beliefs when making decisions about your treatment and care.
Recorded: November 6, 2025
